{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:30:45Z","timestamp":1781811045836,"version":"3.54.5"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Head and neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge due to high recurrence, therapy resistance, and limited biomarkers. The tumor microenvironment (TME) plays a critical role in determining treatment outcomes. Immuno-positron emission tomography (immunoPET), which combines the specificity of monoclonal antibodies (mAbs) with the sensitivity of PET, offers non-invasive visualization of immune activity and guidance for treatment. This review summarizes the applications of immunoPET in HNSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Followed PRISMA 2020 guidelines, 1686 records were identified through searches of PubMed, Embase, Scopus, and Web of Science (January 1, 1999, to May 11, 2025). Only 11 studies on immunoPET in HNSCC met the inclusion criteria and were evaluated for imaging targets, radiotracers, injection approaches, and preclinical or clinical outcomes. Methodological quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six preclinical and five clinical studies investigated five immune-related targets: programmed death-ligand 1 (PD-L1), epidermal growth factor receptor (EGFR), tenascin-C, the extra domain B (ED-B) of fibronectin, and cluster of differentiation 44 variant 6 (CD44v6). PD-L1 imaging demonstrated safety and feasibility but lacked predictive accuracy. EGFR imaging showed high preclinical receptor-specific specificity, whereas clinical performance revealed cetuximab tumor accessibility, which was undetectable by FDG PET, with significant variability between patients. Tenascin-C imaging was localized to tumors but missed some lymph node metastases. ED-B imaging visualized tumor angiogenesis and reliably predicted therapeutic biodistribution, while CD44v6 emerged as the most consistently evaluated and promising for clinical translation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      ImmunoPET holds promise for patient stratification and early response monitoring in HNSCC. Evidence remains limited, primarily due to small cohorts, heterogeneous protocols, narrow target diversity, and reliance on long-lived tracers. Future research should broaden the immune target, optimize imaging protocols, and develop short-lived tracers (e.g.,\n                      <jats:sup>18<\/jats:sup>\n                      F,\n                      <jats:sup>68<\/jats:sup>\n                      Ga) for broader clinical integration.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1644692","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:28:26Z","timestamp":1761204506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Application of immunoPET imaging to enhance head and neck squamous cell carcinoma clinical management"],"prefix":"10.3389","volume":"15","author":[{"given":"Waleed M.","family":"Almutairi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Huang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwaseyi M.","family":"Oderinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4065-5","article-title":"What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis","volume":"45","author":"Bonomo","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.radonc.2007.04.001","article-title":"Tumor progression in waiting time for radiotherapy in head and neck cancer","volume":"84","author":"Jensen","year":"2007","journal-title":"Radiother Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091521","article-title":"Immune cells in head-and-neck tumor microenvironments","volume":"12","author":"Jumaniyazova","year":"2022","journal-title":"J Pers Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canlet.2021.03.009","article-title":"Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms","volume":"507","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"key":"B6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11912-020-00938-3","article-title":"The immune microenvironment in head and neck squamous cell carcinoma: on subsets and subsites","volume":"22","author":"Wondergem","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189289","article-title":"Evaluation of ImmunoPET in the efficacy and prognosis of immunotherapy for lung cancer","volume":"1880","author":"Liang","year":"2025","journal-title":"Biochim Biophys Acta BBA - Rev Cancer"},{"key":"B8","article-title":"Total-Body Dynamic Imaging and Kinetic Modeling of [18 F]F-AraG in Healthy Individuals and a Non\u2013Small Cell Lung Cancer Patient Undergoing Anti\u2013PD-1 Immunotherapy","volume-title":"J Nucl Med","author":"Omidvari","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01067","article-title":"In vivo imaging technologies to monitor the immune system","volume":"11","author":"McCarthy","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02084-8","article-title":"Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1\/2 trial","volume":"28","author":"Kist De Ruijter","year":"2022","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.11.85","article-title":"The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients","volume":"11","author":"Hofman","year":"2019","journal-title":"J Thorac Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3146","article-title":"PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors","volume":"23","author":"Kluger","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/snuc.2002.29272","article-title":"Whole-body FDG-PET imaging in the management of patients with cancer","volume":"32","author":"Hustinx","year":"2002","journal-title":"Semin Nucl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124309","article-title":"Current perspectives on 89Zr-PET imaging","volume":"21","author":"Yoon","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40134-013-0016-x","article-title":"PET\/CT in oncology: current status and perspectives","volume":"1","author":"Czernin","year":"2013","journal-title":"Curr Radiol Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/medsci12030036","article-title":"Prognostic role of pre- and post-treatment [18F]FDG PET\/CT in squamous cell carcinoma of the oropharynx in patients treated with chemotherapy and radiotherapy","volume":"12","author":"Dondi","year":"2024","journal-title":"Med Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better","volume":"52","author":"Im","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318285c135","article-title":"The history of cerebral PET scanning: From physiology to cutting-edge technology","volume":"80","author":"Portnow","year":"2013","journal-title":"Neurology"},{"key":"B20","first-page":"1","article-title":"Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma","volume":"33","author":"Castaldi","year":"2013","journal-title":"Acta Otorhinolaryngol Ital Organo Uff Della Soc Ital Otorinolaringol E Chir Cerv-facc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1039\/B922628C","article-title":"Molecular tracers for the PET and SPECT imaging of disease","volume":"40","author":"Pimlott","year":"2011","journal-title":"Chem Soc Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-021-01652-7","article-title":"ImmunoPET: harnessing antibodies for imaging immune cells","volume":"24","author":"Wu","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1146","article-title":"False positive positron emission tomography\/computed tomography scans in treated head and neck cancers","author":"Cheung","year":"2017","journal-title":"Cureus"},{"key":"B24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.cpet.2015.05.007","article-title":"PET\/computed tomography using new radiopharmaceuticals in targeted therapy","volume":"10","author":"Sharma","year":"2015","journal-title":"PET Clin"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2021.05.010","article-title":"Immune PET imaging","volume":"59","author":"Iyalomhe","year":"2021","journal-title":"Radiol Clin North Am"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.remnie.2022.08.001","article-title":"ImmunoPET in oncology","volume":"41","author":"Mulero","year":"2022","journal-title":"Rev Esp Med Nucl E Imagen Mol Engl Ed"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1231525","article-title":"Editorial: ImmunoPET imaging in disease diagnosis and therapy assessment","volume":"10","author":"Mulero","year":"2023","journal-title":"Front Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: concept, design, and applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00576-4","article-title":"Advances in PET imaging of cancer","volume":"23","author":"Schwenck","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fnume.2024.1360710","article-title":"Advances and challenges in immunoPET methodology","volume":"4","author":"Mohr","year":"2024","journal-title":"Front Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6041821","article-title":"Positron emission tomography (PET) in oncology","volume":"6","author":"Gallamini","year":"2014","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263470","article-title":"89 zr-DFO-durvalumab PET\/CT before durvalumab treatment in patients with recurrent or metastatic head and neck cancer","volume":"63","author":"Verhoeff","year":"2022","journal-title":"J Nucl Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/1535-7163.MCT-16-0352","article-title":"Combining chk1\/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma","volume":"16","author":"Zeng","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00405","article-title":"Immune responses to epidermal growth factor receptor (EGFR) and their application for cancer treatment","volume":"7","author":"Sasada","year":"2016","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20760","article-title":"Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model","volume":"8","author":"Song","year":"2017","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.13910","article-title":"Quantitative assessment of Zirconium-89 labeled cetuximab using PET\/CT imaging in patients with advanced head and neck cancer: a theragnostic approach","volume-title":"Oncotarget","author":"Even","year":"2017"},{"key":"B40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2967\/jnumed.112.111310","article-title":"Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients","volume":"54","author":"Heuveling","year":"2013","journal-title":"J Nucl Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2014.07.011","article-title":"New radiotracers for imaging of vascular targets in angiogenesis-related diseases","volume":"76","author":"Hong","year":"2014","journal-title":"Adv Drug Delivery Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1096-y","article-title":"124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy","volume":"36","author":"Tijink","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.2c00164","article-title":"Pretargeted PET imaging with a TCO-conjugated anti-CD44v6 chimeric mAb U36 and [89 zr]Zr-DFO-PEG5 -tz","volume":"33","author":"Lumen","year":"2022","journal-title":"Bioconjug Chem"},{"key":"B44","first-page":"1271","article-title":"89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies","volume":"44","author":"Verel","year":"2003","journal-title":"J Nucl Med"},{"key":"B45","first-page":"1663","article-title":"Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice","volume":"44","author":"Verel","year":"2003","journal-title":"J Nucl Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-004-1632-8","article-title":"High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy","volume":"31","author":"Verel","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2137","article-title":"Performance of immuno\u2013positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients","volume":"12","author":"B\u00f6rjesson","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.065862","article-title":"Radiation dosimetry of89 zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients","volume":"50","author":"B\u00f6rjesson","year":"2009","journal-title":"J Nucl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235675","article-title":"Clinical application of immunoPET targeting checkpoint inhibitors","volume":"15","author":"Abenavoli","year":"2023","journal-title":"Cancers"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13550-017-0272-5","article-title":"Effective dose estimation for oncological and neurological PET\/CT procedures","volume":"7","author":"Mart\u00ed-Climent","year":"2017","journal-title":"EJNMMI Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143488","article-title":"Clinical applications of immuno-PET in lymphoma: A systematic review","volume":"14","author":"Triumbari","year":"2022","journal-title":"Cancers"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e50740","DOI":"10.7554\/eLife.50740","article-title":"Preclinical murine tumor models: A structural and functional perspective","volume":"9","author":"Guerin","year":"2020","journal-title":"eLife"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1199146","article-title":"Current and potential roles of immuno-PET\/-SPECT in CAR T-cell therapy","volume":"10","author":"Mulgaonkar","year":"2023","journal-title":"Front Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98509","article-title":"Imaging activated T cells predicts response to cancer vaccines","volume":"128","author":"Alam","year":"2018","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.115.161745","article-title":"Influence of statistical fluctuation on reproducibility and accuracy of SUVmax and SUVpeak : A phantom study","volume":"43","author":"Akamatsu","year":"2015","journal-title":"J Nucl Med Technol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.10.018","article-title":"Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? \u2013 Variability induced by different SUV measurements and varying reconstruction methods","volume":"84","author":"Brendle","year":"2015","journal-title":"Eur J Radiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.101733","article-title":"Noise considerations for PET quantification using maximum and peak standardized uptake value","volume":"53","author":"Lodge","year":"2012","journal-title":"J Nucl Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2967\/jnumed.111.093443","article-title":"Impact of the definition of peak standardized uptake value on quantification of treatment response","volume":"53","author":"Vanderhoek","year":"2012","journal-title":"J Nucl Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-12-1379","article-title":"Immuno-PET: A navigator in monoclonal antibody development and applications","volume":"12","author":"Van Dongen","year":"2007","journal-title":"Oncologist"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071868","article-title":"Development of antibody immuno-PET\/SPECT radiopharmaceuticals for imaging of oncological disorders\u2014An update","volume":"12","author":"Dewulf","year":"2020","journal-title":"Cancers"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261976","article-title":"Visualizing T-cell responses: the T-cell PET imaging toolbox","volume":"63","author":"Li","year":"2022","journal-title":"J Nucl Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1089\/cbr.2014.1709","article-title":"Spatial resolution and image qualities of zr-89 on siemens biograph truePoint PET\/CT","volume":"30","author":"Lee","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2953","article-title":"A PET imaging strategy to visualize activated T cells in acute graft-versus-host disease elicited by allogenic hematopoietic cell transplant","volume":"77","author":"Ronald","year":"2017","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1177\/1536012117712638","article-title":"In vivo PET imaging of the activated immune environment in a small animal model of inflammatory arthritis","volume":"16","author":"Franc","year":"2017","journal-title":"Mol Imaging"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1113924","article-title":"The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors","volume":"13","author":"Levi","year":"2023","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/jnen\/nlad110","article-title":"Whole-brain traumatic controlled cortical impact to the left frontal lobe: Magnetic resonance image-based texture analysis","volume":"83","author":"Alanezi","year":"2024","journal-title":"J Neuropathol Exp Neurol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e0215465","DOI":"10.1371\/journal.pone.0215465","article-title":"FDG PET based prediction of response in head and neck cancer treatment: Assessment of new quantitative imaging features","volume":"14","author":"Beichel","year":"2019","journal-title":"PLoS One"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/jop.13089","article-title":"Machine learning and treatment outcome prediction for oral cancer","volume":"49","author":"Chu","year":"2020","journal-title":"J Oral Pathol Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2021.03.017","article-title":"Prediction of the treatment outcome using machine learning with FDG-PET image-based multiparametric approach in patients with oral cavity squamous cell carcinoma","volume":"76","author":"Fujima","year":"2021","journal-title":"Clin Radiol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13550-020-00686-2","article-title":"Predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma","volume":"10","author":"Martens","year":"2020","journal-title":"EJNMMI Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/life14101248","article-title":"The integration of radiomics and artificial intelligence in modern medicine","volume":"14","author":"Maniaci","year":"2024","journal-title":"Life"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102040","article-title":"Positron emission tomography probes for imaging cytotoxic immune cells","volume":"14","author":"Amgheib","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1644692\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:28:27Z","timestamp":1761204507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1644692\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":74,"alternative-id":["10.3389\/fonc.2025.1644692"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1644692","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"article-number":"1644692"}}